中国单中心银屑病生物制剂超反应者与难治者的特征及治疗结局
BMI<25、较低Charlson共病指数、无银屑病关节炎、有银屑病家族史、较低胰岛素抵抗水平与超反应显著相关;BMI≥30、合并非酒精性脂肪肝、较高PASI、较高ESR为难治者的独立预测因素。超反应者治疗持续性好,难治者持续性差且不良事件(尤其矛盾性湿疹)发生率更高。
要点
- 超反应者占19.0%,难治者占4.6%。
- 低BMI、无关节炎、低胰岛素抵抗等预示超反应。
- 高BMI、脂肪肝、高PASI、高ESR预示生物制剂难治。
核心结论
- 研究识别了银屑病患者生物制剂超反应与难治的预测因素,有助于精准选择药物并兼顾持久性与安全性。
研究设计与样本
- 采用多变量logistic回归分析识别超反应者和难治者的预测因素,用Kaplan-Meier法分析药物生存。
主要发现
- BMI<25、较低Charlson共病指数、无银屑病关节炎、有银屑病家族史、较低胰岛素抵抗水平与超反应显著相关。
- BMI≥30、合并非酒精性脂肪肝、较高PASI、较高ESR水平为难治者的独立预测因素。
- 超反应者与生物制剂治疗持续性相关,难治者与持续性差及不良事件(尤其矛盾性湿疹)发生率更高相关。
临床怎么用
- 对具有超反应预测因素(如低BMI、无关节炎、低胰岛素抵抗)的患者,可优先考虑生物制剂并预期良好持续性。
- 对具有难治预测因素(如高BMI、脂肪肝、高PASI、高ESR)的患者,需加强监测和不良反应管理。
局限性
- 单中心研究,患者数量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite advances in the availability of effective biologics in psoriasis over the past decade, clinical characteristics, persistence, and safety associated with treatment response have never been systematically investigated. OBJECTIVES: The objective of this study was to evaluate the factors, persistence, and safety associated with super-response (super-responder, SR) or refractory (biologic-refractory patient, BRP) to biologic agents. METHODS: This retrospective analysis included psoriasis patients who initiated their first biologic therapy. Multivariable logistic regression analysis identified predictors for SRs and BRPs. Drug survival used Kaplan-Meier plot analysis. RESULTS: Seven hundred thirty-seven patients were included (140 SRs [19.0%], 34 BRPs [4.6%]). Body mass index <25, lower Charlson Comorbidity Index, without psoriatic arthritis, with a family history of psoriasis, and lower insulin resistance level were significantly associated with SRs, whereas body mass index ≥30, with nonalcoholic fatty liver disease, higher psoriasis area and severity index, and higher erythrocyte sedimentation rate level were independent predictors of BRPs. SRs were associated with treatment persistence of biologics, but BRPs were linked with poor persistence and higher incidences of adverse events-particularly paradoxical eczema. LIMITATIONS: Single-center study with limited patients. CONCLUSION: Our study identified predictors of response that may facilitate accurate drug targeting with good persistence and reassuring safety for psoriasis patients.
引用
- Liu Y, Hu K, Duan Y, et al. Characterization and treatment outcomes of biologic therapy in super-responders and biologic-refractory psoriasis patients: A single-center retrospective study in China. J Am Acad Dermatol. 2025. PMID: 40020926. doi:10.1016/j.jaad.2025.02.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。